Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center Study

Background Acute myeloid leukemia (AML) patients are at high risk of infections during post-induction neutropenia. Recently, the role of antibacterial prophylaxis has been reconsidered due to concerns about the emergence of multi-resistant pathogens. The aim of the present study was to evaluate the impact of avoiding prophylaxis on the rate of induction death (primary endpoint), neutropenic fevers, bloodstream infections (BSIs), resistant pathogens BSIs and septic shocks (secondary endpoints). Methods We performed a retrospective single-center study including 373 AML patients treated with intensive induction chemotherapy, divided into two groups according to levofloxacin prophylaxis given (group A, gA) or not (group B, gB). Results Neutropenic fever was observed in 91% of patients in gA and 97% in gB (OR 0.35, IC95% 0.08 – 1.52, p=0162). The rate of BSIs was 27% in gA compared to 34% in gB (OR 0.69, 0.38 – 1.25, p=0.222). The induction death rate was 5% in gA and 3% in gB (OR 1.50, 0.34 – 6.70, p=0.284). Fluoroquinolones (FQ) resistant pathogens were responsible for 59% of total BSIs in gA and 22% in gB (OR 5.07, 1.87 – 13.73, p=0.001); gram-negative BSIs due to multi-drug resistant organisms were 31% in gA and 36% in gB (OR 0.75, 0.15 – 3.70, p=0.727). Conclusions Despite its limitations (retrospective nature, single-center, different cohort size), the present study showed that avoiding levofloxacin prophylaxis was not associated with an increased risk of induction death. The cumulative incidence of neutropenic fever was higher in non-prophylaxis group, while no difference was observed for BSIs. In the prophylaxis group we observed a higher incidence of FQ-resistant organisms.

[1]  D. Buchheidt,et al.  Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) , 2020, Annals of Hematology.

[2]  M. Boccadoro,et al.  FLAI induction regimen in elderly patients with acute myeloid leukemia , 2019, Leukemia & lymphoma.

[3]  M. Chayakulkeeree,et al.  Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis , 2019, Hematology.

[4]  C. Flowers,et al.  Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Pagano,et al.  Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria , 2018, Annals of Hematology.

[6]  P. Bruzzi,et al.  Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. , 2018, The Journal of infection.

[7]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[8]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[9]  M. Aapro,et al.  Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[11]  H. Rohde,et al.  A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. , 2014, The Journal of antimicrobial chemotherapy.

[12]  R. Evans European Centre for Disease Prevention and Control. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[13]  F. D. De Rosa,et al.  Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis , 2013, BMC Infectious Diseases.

[14]  M. Lichtman A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. , 2013, Blood cells, molecules & diseases.

[15]  S. Berendse,et al.  Prevention and management of neutropenic sepsis in patients with cancer: summary of NICE guidance , 2012, BMJ : British Medical Journal.

[16]  L. Mileshkin,et al.  Use of antibacterial prophylaxis for patients with neutropenia , 2011, Internal medicine journal.

[17]  D. Warren,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  L. Leibovici,et al.  Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients , 2007 .

[19]  R. Foà,et al.  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.

[20]  F. Cainelli,et al.  Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. , 2003, The Lancet. Oncology.

[21]  B. Czepulkowski,et al.  Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia , 1997, British journal of haematology.